DIA
CHRS icon

Dana Investment Advisors’s Coherus Oncology CHRS Stock Holding History

Dana Investment Advisors’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-93,814
Closed -$1.52M – 267
2020
Q1 		$1.52M Sell
93,814
-64,531
-41% -$1.19M 0.09% 120
2019
Q4 		$2.85M Buy
158,345
+14,618
+10% +$270K 0.14% 101
2019
Q3 		$2.91M Buy
+143,727
New +$2.87M 0.15% 93

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Dana Investment Advisors's CHRS Position: Q2 2020 in Review

Dana Investment Advisors sold out of Coherus Oncology (CHRS) in Q2 2020, closing a stake of 93,814 shares — an estimated $1.52M sold.

Dana Investment Advisors first reported a position in CHRS in Q3 2019 and held it in 3 quarters. The position peaked at $2.91M in Q3 2019. 188 funds tracked by Wall St. Rank hold CHRS as of Q2 2020.

  • Dana Investment Advisors reported no remaining Coherus Oncology position as of Q2 2020 after selling out during the quarter.
  • Dana Investment Advisors sold 93,814 Coherus Oncology shares in Q2 2020, an estimated $1.52M.
  • Dana Investment Advisors first reported a position in Coherus Oncology in Q3 2019 and held it in 3 quarters.
  • Dana Investment Advisors's Coherus Oncology position peaked at $2.91M in Q3 2019.
  • 188 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2020.

Based on Dana Investment Advisors's 13F filing for Q2 2020, filed 11 Aug 2020.